How did Rapamycin get its name and what is its origin?

Rapamycin was discovered from soil samples collected on Easter Island, also known as Rapa Nui, in the South Pacific. It was isolated from a bacterium called Streptomyces hygroscopicus and named in deference to the island. This discovery was made in the 1960s, with its chemical composition described in the early 1970s.

Why did Rapamycin's clinical development for longevity take so long?

Rapamycin's clinical path was slowed because it was initially developed and approved as an immunosuppressant for organ transplant patients, leading to a reputation as a dangerous drug due to high dosing and co-administration with other toxic drugs. This history negatively impacted its exploration for other uses, as patents expired before its full potential for aging benefits was widely recognized.

What was the significance of the 2009 Interventions Testing Program (ITP) study for Rapamycin?

The ITP study in 2009 was the first to convincingly show Rapamycin could extend lifespan in mice, even when treatment started in middle age. This was a groundbreaking discovery that challenged the assumption that longevity interventions only worked if administered early in life, opening up new translational possibilities for treating middle-aged animals and humans.

How does Rapamycin specifically interact with the mTOR protein?

Unlike most drugs that directly inhibit a protein, Rapamycin acts as a 'molecular glue.' It binds to a small protein called FKBP12, and this complex then binds to mTOR, sterically hindering certain large substrates from accessing mTOR's catalytic site. This results in a partial inhibition of mTOR Complex 1 (mTORC1) and, over prolonged exposure, affects the formation of mTOR Complex 2 (mTORC2).

What role do amino acids, particularly Lucine, play in mTOR activation?

mTOR is a crucial sensor of nutrient availability. Amino acids, especially Lucine, signal to mTOR. When a cell has abundant Lucine, it binds to a receptor called sestrin, initiating a cascade that leads to mTOR's localization on lysosomes, activating its anabolic functions. This pathway ensures cells grow and synthesize proteins when nutrients are available.

How does Rapamycin's inhibition of mTOR reconcile with the importance of muscle mass and amino acids for older adults?

While mTOR activation is crucial for muscle synthesis, studies in rodents show that Rapamycin, at longevity-extending doses, can actually preserve muscle mass in old age. The explanation is complex; it's hypothesized that Rapamycin's anti-inflammatory effects counteract age-related inflammation that contributes to muscle loss (sarcopenia), effectively preserving muscle despite some direct inhibition of protein synthesis.

Does Rapamycin penetrate the blood-brain barrier, and what are the implications for brain health?

The penetration of Rapamycin into the brain is debated and appears dose-dependent. Some studies suggest it needs higher or repeated dosing to cross effectively. However, it's hypothesized that Rapamycin's effects on the peripheral immune system and chronic inflammation may indirectly benefit brain health, even without high brain concentrations, by reducing systemic inflammation that affects brain function.

What was the human study on Everolimus (a Rapamycin derivative) and immune function?

A milestone study by Joan Mannick and others in 2014 involved healthy older adults receiving Everolimus (a rapalog) for six weeks. It showed that low doses (5mg once weekly or 1mg daily) significantly boosted the immune response to a flu vaccine, rejuvenating the aged immune system with a side effect profile similar to placebo. This study shifted perspective on Rapamycin from an immunosuppressant to an immune modulator.

What did the recent survey of Rapamycin users reveal about its side effects and impact on COVID-19?

A survey of over 300 off-label Rapamycin users found no significant side effects compared to non-users, except for mouth sores (reported by ~15%). Interestingly, it suggested lower rates of depression and anxiety. For COVID-19, continuous Rapamycin users reported lower severity of infection and reduced likelihood of long COVID, though these findings are suggestive due to the self-reported nature of the study.

Why does David Sabatini, a leading Rapamycin expert, choose not to take Rapamycin?

David Sabatini questions whether Rapamycin offers significant additional benefits if one already maintains a healthy diet and exercises, as it might mimic some of the effects of these lifestyle choices. He is more interested in exploring approaches that can achieve metabolic states or impacts on the system that cannot be replicated through diet alone, possibly using highly specific, intermittent catalytic inhibitors.

What is the Dog Aging Project and what does it hope to learn about Rapamycin?

Led by Matt Kaeberlein, the Dog Aging Project is a double-blind, randomized, placebo-controlled clinical trial involving 580 companion dogs over 7 years old. It aims to determine if Rapamycin can slow aging, increase lifespan, and improve healthspan metrics like cardiac, neurological, and cognitive function over a 3-year treatment period. It utilizes dogs as a model closer to humans, aging more rapidly and living in diverse environments.

What are the current understandings of Rapamycin's impact on reproductive aging?

In female mice, transient Rapamycin treatment can delay or even reverse ovarian atrophy and restore reproductive capacity. However, in male mice, it appears to impair spermatogenesis, potentially inducing sterility, though this may be reversible. Clinical trials are ongoing, studying Rapamycin's effect on women with premature ovarian failure, including measuring anti-Müllerian hormone (AMH) levels.

Key Moments

272 ‒ Rapamycin: potential longevity benefits, surge in popularity, unanswered questions, and more

Peter Attia MD

Science & Technology8 min read182 min video

Sep 25, 2023|130,853 views|1,723|180

Peter Attia MD Dr. Peter Attia Early Medical The Drive Podcast The Drive Longevity Zone 2

Save to Pod

Key Moments

On this page

TL;DR

Rapamycin's longevity potential, detailed mechanisms, current human and animal studies, and future research challenges.

Key Insights

Rapamycin (Rapa), initially an immunosuppressant, is now considered the most robust and reproducible drug in preclinical studies for extending lifespan and health span across a broad evolutionary spectrum.

mTOR, the target of Rapamycin, is a critical protein complex that links nutrient availability to cellular states (anabolic for growth, catabolic for breakdown), explaining its widespread physiological roles.

Rapamycin's unique allosteric inhibition of mTOR Complex 1 (mTORC1) and delayed inhibition of mTOR Complex 2 (mTORC2) differentiates it from more toxic catalytic mTOR inhibitors, affecting specific substrates and cellular processes like autophagy.

Early clinical studies, particularly a 2014 trial with everolimus (a Rapa derivative), demonstrated that low, transient doses could rejuvenate the immune system in older adults with minimal side effects, paving the way for broader geroprotective applications.

Ongoing and future research, including the Dog Aging Project and human trials, aim to definitively establish dosing, efficacy, and safety for healthy aging, moving beyond disease-specific applications.

Significant challenges remain in funding non-commercial, fundamental research, understanding optimal dosing, tissue specificity, and the precise molecular mechanisms of Rapamycin's diverse effects across the numerous hallmarks of aging.

THE ROBUST POTENTIAL OF RAPAMYCIN

Rapamycin (Rapa) stands out as the most consistent and effective drug in preclinical studies for extending lifespan and health span, spanning organisms from yeast to mice and potentially dogs. Its impact extends beyond longevity, positively influencing various health span metrics in complex animals. This wide-ranging efficacy is a primary driver behind its increasing popularity in longevity research, even though the drug was initially developed and approved as an immunosuppressant following organ transplantation.

THE DISCOVERY AND SURGE IN POPULARITY

Discovered in the 1960s from soil samples on Easter Island (Rapa Nui), Rapamycin's journey to recognition as a longevity agent was slow, with FDA approval for human use only coming in 1999. The initial clinical application as an immunosuppressant for organ transplant patients, involving high daily doses in combination with other toxic drugs, created a reputation for severe side effects. This history has arguably slowed its development for other uses, as researchers needed to overcome the perception of it being a 'dangerous drug.' The 2009 Interventions Testing Program (ITP) study, which showed Rapamycin extended lifespan in middle-aged mice, was a critical turning point.

MTOR: THE MASTER NUTRIENT SENSOR

David Sabatini's early work elucidated that Rapamycin targets mTOR (mechanistic Target of Rapamycin), a protein kinase functioning as a central regulator linking nutrient availability to cellular states. mTOR orchestrates a cell's decision to enter an anabolic (growth) or catabolic (breakdown) state, influencing nearly all physiological processes. This fundamental role in nutrient sensing explains mTOR's broad impact across evolution, from single-celled organisms to mammals. Rapamycin's action via nutrient deprivation mimics the effects of caloric restriction, a known life-extending intervention across species.

THE COMPLICATED MECHANISM OF MTOR INHIBITION

Rapamycin is an allosteric inhibitor, meaning it binds to mTOR via an intermediary protein (FKBP) and partially blocks the active site of mTOR Complex 1 (mTORC1), preventing certain substrates from binding. This partial inhibition differs significantly from catalytic inhibitors, which fully abolish mTORC1 and mTOR Complex 2 (mTORC2) activity and are acutely toxic. Chronically, Rapamycin can also inhibit mTORC2 by preventing its formation, but the extent and implications of mTORC2 inhibition at lower, intermittent doses for longevity benefits remain unclear and a subject of ongoing debate. The analogy of 'on/off switches' is misleading; mTOR activity is more like a 'knob' that can be modulated.

AMINO ACIDS AND MTOR REGULATION

A significant breakthrough in understanding mTOR's nutrient sensing came with the discovery of its localization to lysosomes—cellular recycling centers. Research, particularly by David Sabatini's lab, identified that amino acids, especially leucine, signal to mTOR, causing it to dock at the lysosome and activate. The discovery of sestrin as the specific leucine receptor provided a molecular understanding of how dietary protein intake directly influences mTOR activity. This connection highlights the critical balance between anabolic signaling, essential for muscle maintenance, and the longevity benefits associated with reduced mTOR activity.

RECONCILING ANABOLISM AND LONGEVITY

The apparent conflict between the importance of anabolic signaling for muscle mass (to combat sarcopenia) and mTOR inhibition for longevity is complex. While mTOR activation is undoubtedly crucial for muscle growth and repair, studies in rodents show that Rapamycin, at lifespan-extending doses, can preserve muscle mass into old age, potentially by mitigating chronic inflammation that contributes to sarcopenia. The nuanced effects suggest that optimal mTOR activity for longevity may involve a delicate balance, rather than complete suppression, where the benefits of reduced inflammation and enhanced autophagy outweigh potential transient reductions in muscle protein synthesis. Extrapolating rodent muscle studies to humans, however, requires caution due to species-specific sarcopenia characteristics.

TISSUE SPECIFICITY AND CNS PENETRATION

The tissue-specific effects of Rapamycin are not fully understood, particularly at the low, intermittent doses being explored for longevity. While high doses can inhibit mTORC1 across most tissues, including the brain after repeated administration, the extent and uniformity of inhibition at lower doses, especially in the central nervous system (CNS), are debated. The blood-brain barrier's decline with age might allow better CNS penetration in older individuals, but direct evidence is scarce. Research suggests that peripheral effects, such as reduced inflammation in the liver or immune system, could indirectly benefit brain health, as seen in certain mouse models of neurodegeneration.

THE IMMUNE MODULATOR: EVEROLIMUS AND THE JOAN MANICK STUDY

The 2014 study led by Joan Mannick, using everolimus (an Rapamycin derivative), marked a pivotal moment, demonstrating immune rejuvenation in healthy older adults. Transient, low-dose everolimus significantly boosted the immune response to influenza vaccination, establishing Rapamycin derivatives not just as immunosuppressants but as immune modulators capable of enhancing the aged immune system. Crucially, the study showed that lower doses (5mg weekly) were well-tolerated, with a side effect profile similar to placebo, primarily notable for mouth sores. This study provided strong clinical evidence for the safety and efficacy of mTOR inhibition in humans for geroprotective ends, challenging long-held assumptions from transplant settings.

EPIGENETIC IMPACTS AND HALLMARKS OF AGING

While Rapamycin impacts numerous hallmarks of aging, its specific effect on epigenetic changes—one of the core hallmarks—remains less clear compared to, say, nutrient signaling or proteostasis. Researchers hypothesize that Rapamycin's broad effects, such as reducing chronic inflammation and reactivating autophagy, could indirectly lead to epigenetic shifts. However, direct molecular evidence for specific mTOR-regulated epigenetic pathways is elusive. The observed immune rejuvenation in aging individuals via Rapamycin may be a functional resetting of the immune system, where chronic sterile inflammation is reduced, allowing cells to respond more effectively, rather than a direct 'reversal' of epigenetic age clocks.

CYCLING AND DOSING REGIMENS: LEARNING FROM REAL-WORLD USE

The optimal dosing regimen (continuous vs. intermittent) for human longevity is largely unknown and undergoing investigation. While ITP mouse studies used continuous, low-dose administration, many off-label human users, influenced by studies like Mannick's, adopt intermittent weekly dosing (e.g., 6mg once weekly). A survey of Rapamycin users corroborated that mouth sores are the most common side effect, but also hinted at potential benefits for depression and anxiety, aligning with emerging literature on mTOR's role in neurocognitive function. The efficacy of intermittent dosing in humans, particularly concerning CNS penetration and sustained effects, requires robust clinical trials.

AUTOPHAGY AND INFLAMMATION: KEY DRIVERS OF BENEFIT

Among the myriad downstream effects of mTOR inhibition, David Sabatini emphasizes autophagy—the cellular process of self-eating and recycling—as a prominent driver of Rapamycin's health benefits. Enhanced autophagy is crucial for breaking down damaged cellular components and promoting cellular rejuvenation. Matt Kaeberlein, however, highlights the anti-inflammatory effects of Rapamycin, particularly its ability to dampen sterile inflammation in aged animals and humans, as a plausible explanation for many observed functional improvements. Both mechanisms likely contribute, with their relative importance varying depending on the tissue and disease context. The lack of reliable human biomarkers for autophagy remains a significant hurdle for research.

COMPANION ANIMALS: REAL-WORLD INSIGHTS

The Dog Aging Project, led by Matt Kaeberlein, represents a landmark effort to study Rapamycin's effects on longevity and health span in pet dogs. Dogs age more rapidly than humans, live in shared environments, and offer a more translatable model than mice. This double-blind, placebo-controlled clinical trial aims to detect a 9% increase in lifespan in middle-aged dogs, powered by a significant cohort size. The study also investigates Rapamycin's impact on various health span metrics, including cardiac, neurological, and cognitive function. The results, anticipated around 2026, are highly awaited, as they could validate Rapamycin's potential in a more ecologically relevant model, with tangible value for pet owners and insights for human aging.

OVARIAN AGING AND FERTILITY: A FRUSTRATED RESEARCH AREA

Research on Rapamycin's impact on ovarian aging and fertility is a critical yet underfunded area. Mouse studies have shown that transient Rapamycin treatment can delay or even reverse ovarian atrophy and restore reproductive capacity in female mice, potentially by influencing the slow proliferation rates of oocytes. In contrast, it appears to impair spermatogenesis in male mice. While human trials are beginning to investigate Rapamycin's effects on premature ovarian failure and reproductive function, the lack of substantial funding for non-commercial research hinders progress in this socially important field. The potential to preserve sperm and egg health remains a fascinating, underexplored avenue.

LOOKING FORWARD: CHALLENGES AND NEW FRONTIERS

The current landscape of Rapamycin research is marked by a growing consensus on mTOR's importance as a target, yet a persistent challenge in funding fundamental, non-commercial studies. While Rapamycin and its derivatives (rapalogs) are actively being explored, there's limited interest in investigating other components of the mTOR pathway that could offer novel therapeutic avenues. The slow pace of clinical translation, despite Rapamycin's existing regulatory approval, underscores the need for new funding models and streamlined research approaches to fully unlock its geroprotective potential. Understanding the optimal dosing, tissue specificity, and the precise molecular mechanisms remains crucial for future applications.

Mentioned in This Episode

●Supplements

●Companies

●Organizations

●People Referenced

Common Questions

Rapamycin is a drug that inhibits the mTOR protein, a master regulator of cell growth. Preclinical studies across diverse organisms like yeast, worms, fruit flies, and mice consistently show it robustly extends lifespan and improves healthspan parameters. It is unique in its reproducible and broad impact on aging processes.